Johns Hopkins ABX Guide
Baloxavir
INDICATIONS
FDA
FDA
- Treatment of uncomplicated influenza in patients aged ≥5 years with symptoms < 48 hours.
- Limitations of use:
- Consider susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir, as viruses change over time; changes in virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.
- Baloxavir carries the FDA label for individuals at high risk of influenza (based on the Capstone 2 trial).
- Limitations of use:
- Post-exposure prophylaxis (PEP) in patients ≥5 years
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 6, 2026
Citation
Dzintars, Kate, and Paul G Auwaerter. "Baloxavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir.
Dzintars K, Auwaerter PG. Baloxavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir. Accessed September 16, 2026.
Dzintars, K., & Auwaerter, P. G. (2026). Baloxavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir
Dzintars K, Auwaerter PG. Baloxavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 September 16]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Baloxavir
ID - 540707
A1 - Dzintars,Kate,Pharm.D., BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2026/09/06/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/all/Baloxavir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
